Primatene Mist NDA Expected By July After FDA OKs OTC Asthma Inhaler Trial
This article was originally published in The Pink Sheet & The Rose Sheet
Executive SummaryAmphastar plans this month to begin what it expects to be its final study to support an NDA to relaunch Primatene Mist. If the results support accurate self-selection and usage of the product by consumers, Amphastar should be ready to re-submit the NDA during the current quarter.
You may also be interested in...
Second FDA complete response letter for a reformulated Primatene Mist likely pushes back by another 18 months Amphastar's potential relaunch of the OTC product after satisfying the US agency's concerns about consumers correcting using the product without a doctor’s intervention.
Dr. Natural Healing markets its Prime Asthma Relief Start Kit with an epinephrine delivery form – a capsule added to a dry powder inhaler – not approved under the OTC bronchodilator monograph, FDA says in a warning letter, its latest enforcement against OTC asthma inhalers it considers noncompliant.